BioXcel Therapeutics

BioXcel Therapeutics is a clinical-stage biopharmaceutical company leveraging AI to discover and develop innovative therapies in neuroscience and immuno-oncology.

Headquarters

Year Founded

Company Status

Website

Sector

Operating Status

Social Media

Search Tags

AI-driven Drug Development, Neuroscience Therapeutics, Drug Re-innovation

About Us

BioXcel Therapeutics is a biopharmaceutical company that develops innovative medicines using artificial intelligence. The company focuses on neuroscience and immuno-oncology, employing a drug re-innovation strategy that repurposes existing approved drugs with advanced machine learning techniques. Its lead product, IGALMI, is designed for treating agitation in patients with schizophrenia or bipolar disorders. BioXcel is also advancing treatments for conditions such as Alzheimer’s disease and various cancers, aiming to address significant unmet medical needs in these areas.

Trending Companies in AI

Latest Articles in AI

Medicare will pilot AI-driven prior authorization in 2026 across six states, targeting high-risk services while clinicians make final decisions.

AI-Powered Prior Authorization Comes to Traditional Medicare

Traditional Medicare will pilot AI-assisted prior authorization in 2026 across six states, focusing on high-risk outpatient services. Clinicians retain final say, but incentives and access concerns loom as CMS tests fraud reduction and “gold card” exemptions. Here’s what providers and patients should know.

Read More >
Anycubic Photon Mono M7 Pro for $469 with code AC30OFF. FREE $99 Gifts: 1*High Speed Resin+2*FEP Film+3000pcs Limited Mystery Box

CREATORS. DISRUPTORS. INNOVATORS.

Discover Emerging Technology Companies